Multiple myeloma therapies are evolving rapidly. Recently, in Portugal, the inhibition of the NFIL3-MYC axis has shown to overcome treatment resistance in high-risk patients. New approaches, such as CAR-T therapies and antibody combinations, are being explored in various countries, including Canada and the USA, with the aim of improving access to treatments.
Made by MielomaAI On November 17, 2026, at 11:05, based on recent news. May contain errors. View news →
In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MDThe American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAA single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Sunday, November 15
Why Multiple Myeloma’s Standard of Care Could Change Again Within a YearCancerNetwork (EUA) · 18:05 TratamentosEUACancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Friday, November 13
My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 13:00 TratamentosEUAMy Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma | OncLive Insights | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Thursday, November 12th
Referral Before Salvage Therapy Keeps CAR T an Option in MyelomaTargeted Onc (EUA) · 22:08 TratamentosEUADuring a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
How Etentamig Stands Out From Other BCMA BispecificsTargeted Onc (EUA) · 22:00 TratamentosEUAPeter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…
CELMoDs as Holding and Bridging Therapy in Multiple MyelomaCancerNetwork (EUA) · 15:43 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple MyelomaCancerNetwork (EUA) · 13:13 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
Wednesday, 11/11
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma CohortCancerNetwork (EUA) · 20:08 TratamentosEUAIn a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Tuesday, November 10
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
Monday, November 9th
Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaOncLive (EUA) · 21:41 TratamentosEUAThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Friday, November 6th
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Wednesday, 11/04
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.
Tuesday, November 3rd
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
Monday, 02/11
Frontline Treatment in Multiple Myeloma Is ChangingMedPage Today (EUA) · 08:00 TratamentosEUAExperts discuss the broader use of four-drug regimens and whether treatment can be shortened
Sunday, November 1st
Myeloma Is Many Diseases, and Treatment Must Reflect ThatThe American Journal of Managed Care (EUA) · 07:00 TratamentosEUANikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.
Thursday, October 29th
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?CancerNetwork (EUA) · 17:09 TratamentosEUA“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
